Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
NEW YORK, Feb. 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Ophthotech Corporation (NASDAQ:OPHT) securities between May 11, 2015 and December 12, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/ophthotech-corporation. There is no cost or obligation to you.
According to the complaint, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.
If you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/ophthotech-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
